A population-based case-control study of oral griseofulvin treatment during pregnancy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: To study the teratogenicity of oral griseofulvin during pregnancy. Methods: The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 and the Hungarian Congenital Abnormality Registry between 1970 and 2002 were evaluated. Results: In total, 38 151 pregnant women who delivered newborn infants without any defects (control group) and 22 843 pregnant women who had fetuses or newborns with congenital abnormalities were included in the study. Seven (0.03%) case and 24 (0.06%) control pregnant women were treated with the griseofulvin (crude odds ratio with 95% confidence interval: 0.49, 0.21-1.13). A teratogenic potential of griseofulvin was not indicated by a comparison of the expected and observed number of different congenital abnormalities. A higher mean birth weight was found in control newborn infants born to mothers with griseofulvin treatment compared with the data of control newborn infants without this treatment. In addition, 55 conjoined twins were evaluated in the data set of the Hungarian Congenital Abnormality Registry, and no conjoined twins had mother with griseofulvin treatment during pregnancy. Conclusion: Our data do not indicate a detectable teratogenic risk of oral griseofulvin treatment during pregnancy; however, the numbers of cases and controls were limited. Therefore, international collaboration is needed for the final conclusion.

Original languageEnglish
Pages (from-to)827-831
Number of pages5
JournalActa Obstetricia et Gynecologica Scandinavica
Volume83
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Griseofulvin
Case-Control Studies
Pregnancy
Conjoined Twins
Newborn Infant
Population
Pregnant Women
Registries
Therapeutics
Mothers
Birth Weight
Fetus
Odds Ratio
Confidence Intervals
Control Groups

Keywords

  • Birth weight
  • Case-control study
  • Congenital abnormalities
  • Griseofulvin

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

A population-based case-control study of oral griseofulvin treatment during pregnancy. / Czeizel, E.; Métneki, J.; Kazy, Zoltán; Puhó, E.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 83, No. 9, 09.2004, p. 827-831.

Research output: Contribution to journalArticle

@article{b26be2f3ef4a4873a258aeb88e79cbe8,
title = "A population-based case-control study of oral griseofulvin treatment during pregnancy",
abstract = "Aim: To study the teratogenicity of oral griseofulvin during pregnancy. Methods: The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 and the Hungarian Congenital Abnormality Registry between 1970 and 2002 were evaluated. Results: In total, 38 151 pregnant women who delivered newborn infants without any defects (control group) and 22 843 pregnant women who had fetuses or newborns with congenital abnormalities were included in the study. Seven (0.03{\%}) case and 24 (0.06{\%}) control pregnant women were treated with the griseofulvin (crude odds ratio with 95{\%} confidence interval: 0.49, 0.21-1.13). A teratogenic potential of griseofulvin was not indicated by a comparison of the expected and observed number of different congenital abnormalities. A higher mean birth weight was found in control newborn infants born to mothers with griseofulvin treatment compared with the data of control newborn infants without this treatment. In addition, 55 conjoined twins were evaluated in the data set of the Hungarian Congenital Abnormality Registry, and no conjoined twins had mother with griseofulvin treatment during pregnancy. Conclusion: Our data do not indicate a detectable teratogenic risk of oral griseofulvin treatment during pregnancy; however, the numbers of cases and controls were limited. Therefore, international collaboration is needed for the final conclusion.",
keywords = "Birth weight, Case-control study, Congenital abnormalities, Griseofulvin",
author = "E. Czeizel and J. M{\'e}tneki and Zolt{\'a}n Kazy and E. Puh{\'o}",
year = "2004",
month = "9",
doi = "10.1111/j.0001-6349.2004.00598.x",
language = "English",
volume = "83",
pages = "827--831",
journal = "Acta Obstetricia et Gynecologica Scandinavica, Supplement",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - A population-based case-control study of oral griseofulvin treatment during pregnancy

AU - Czeizel, E.

AU - Métneki, J.

AU - Kazy, Zoltán

AU - Puhó, E.

PY - 2004/9

Y1 - 2004/9

N2 - Aim: To study the teratogenicity of oral griseofulvin during pregnancy. Methods: The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 and the Hungarian Congenital Abnormality Registry between 1970 and 2002 were evaluated. Results: In total, 38 151 pregnant women who delivered newborn infants without any defects (control group) and 22 843 pregnant women who had fetuses or newborns with congenital abnormalities were included in the study. Seven (0.03%) case and 24 (0.06%) control pregnant women were treated with the griseofulvin (crude odds ratio with 95% confidence interval: 0.49, 0.21-1.13). A teratogenic potential of griseofulvin was not indicated by a comparison of the expected and observed number of different congenital abnormalities. A higher mean birth weight was found in control newborn infants born to mothers with griseofulvin treatment compared with the data of control newborn infants without this treatment. In addition, 55 conjoined twins were evaluated in the data set of the Hungarian Congenital Abnormality Registry, and no conjoined twins had mother with griseofulvin treatment during pregnancy. Conclusion: Our data do not indicate a detectable teratogenic risk of oral griseofulvin treatment during pregnancy; however, the numbers of cases and controls were limited. Therefore, international collaboration is needed for the final conclusion.

AB - Aim: To study the teratogenicity of oral griseofulvin during pregnancy. Methods: The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 and the Hungarian Congenital Abnormality Registry between 1970 and 2002 were evaluated. Results: In total, 38 151 pregnant women who delivered newborn infants without any defects (control group) and 22 843 pregnant women who had fetuses or newborns with congenital abnormalities were included in the study. Seven (0.03%) case and 24 (0.06%) control pregnant women were treated with the griseofulvin (crude odds ratio with 95% confidence interval: 0.49, 0.21-1.13). A teratogenic potential of griseofulvin was not indicated by a comparison of the expected and observed number of different congenital abnormalities. A higher mean birth weight was found in control newborn infants born to mothers with griseofulvin treatment compared with the data of control newborn infants without this treatment. In addition, 55 conjoined twins were evaluated in the data set of the Hungarian Congenital Abnormality Registry, and no conjoined twins had mother with griseofulvin treatment during pregnancy. Conclusion: Our data do not indicate a detectable teratogenic risk of oral griseofulvin treatment during pregnancy; however, the numbers of cases and controls were limited. Therefore, international collaboration is needed for the final conclusion.

KW - Birth weight

KW - Case-control study

KW - Congenital abnormalities

KW - Griseofulvin

UR - http://www.scopus.com/inward/record.url?scp=4444340571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444340571&partnerID=8YFLogxK

U2 - 10.1111/j.0001-6349.2004.00598.x

DO - 10.1111/j.0001-6349.2004.00598.x

M3 - Article

C2 - 15315593

AN - SCOPUS:4444340571

VL - 83

SP - 827

EP - 831

JO - Acta Obstetricia et Gynecologica Scandinavica, Supplement

JF - Acta Obstetricia et Gynecologica Scandinavica, Supplement

SN - 0001-6349

IS - 9

ER -